Latest news
Tenax's oral levosimendan misses primary endpoint in Phase 3 LEVEL PH-HFpEF trial - DealroomDealroom · Mon, 10 Aug 2026 16:55:56 GMTTenax’s levosimendan fails Phase III LEVEL trial in PH-HFpEF - AllSciAllSci · Mon, 10 Aug 2026 16:40:47 GMTTNX-103 Misses Primary Endpoint in Phase 3 LEVEL PH-HFpEF Trial - HCPLiveHCPLive · Mon, 10 Aug 2026 15:00:00 GMTTenax sees 'clear path forward' for heart failure drug despite Phase III miss - FirstWord PharmaFirstWord Pharma · Mon, 10 Aug 2026 13:48:18 GMTTenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF - Investing News NetworkInvesting News Network · Mon, 10 Aug 2026 12:54:11 GMTHeart failure drug from Tenax Therapeutics fails in pivotal study - statnews.comstatnews.com · Mon, 10 Aug 2026 11:43:53 GMTTENX: TNX-103 missed primary endpoints in PH-HFpEF but showed strong biomarker and subgroup benefits - tradingview.comtradingview.com · Mon, 10 Aug 2026 11:26:10 GMTOrion’s license partner Tenax Therapeutics’ Phase 3 LEVEL trial of oral levosimendan in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) did not reach its primary endpoint - The Manila TimesThe Manila Times · Mon, 10 Aug 2026 11:19:58 GMT